Health Services Bdsx

Biodesix, Inc.

BDSX | $1.26 -1.56% -1.59% 7.1K

(0.0% 1d) (-11.1% 1m) (-20.0% 1y) (0.0% 2d) (-0.8% 3d) (2.4% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 122,146,997
http://www.biodesix.com
Sec Filling | Patents | n/a employees

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.

cancer lung cancer genomic t-cell lungs diagnostics ceiling

add to watch list Paper trade email alert is off

Press-releases

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
Published: 2024-04-24 (Crawled : 11:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| Email alert Add to watchlist
first report financial results

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| -15.23% | O: -13.25% H: 14.5% C: 6.87%
offering

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
Published: 2024-03-25 (Crawled : 12:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| -7.25% | O: 4.35% H: 5.56% C: 0.0%
cancer research agreement

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
Published: 2024-03-01 (Crawled : 12:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| -16.88% | O: 23.38% H: 1.58% C: -16.84%
business year results

Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-26 (Crawled : 12:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| -18.99% | O: 1.27% H: 1.87% C: -4.38%
conference health care

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
Published: 2024-02-16 (Crawled : 12:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| -18.47% | O: -1.27% H: 6.06% C: -4.52%
report year financial results

Global Proteomics Strategic Research Report 2023-2030 - U.S. Market is Estimated at $11.5 Billion, While China is Forecast to Grow at 12.8% CAGR
Published: 2023-12-07 (Crawled : 00:00) - prnewswire.com
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| -14.67% | O: 2.67% H: 7.14% C: 3.25%
report research global china market

Biodesix Announces Third Quarter 2023 Results and Highlights
Published: 2023-11-07 (Crawled : 00:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

| -11.72% | O: 6.55% H: 6.15% C: -4.21%
results

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
Published: 2023-10-24 (Crawled : 11:00) - biospace.com/
BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services